For The Second Year, 20 Women Entrepreneurs Will Each Receive $25,000 In Funding, Plus Access to Mentorship and Community—Helping to Close the Confidence GapIRVINE, Calif., June 11, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV) revealed this year's 20 BOTOX® Cosmetic grant recipients. Each inspiring woman entrepreneur will receive a $25,000 grant, mentorship, and access to community through the BOTOX® Cosmetic grant program in partnership with IFundWomen. The winners were h ...

AbbVie (ABBV) ended the recent trading session at $170.46, demonstrating a +0.61% swing from the preceding day's closing price. This change outpaced the S&P 500's 0.26% gain on the day. At the same time, the Dow added 0.18%, and the tech-heavy Nasdaq gained 0.35%.The drugmaker's stock has climbed by 5.39% in the past month, exceeding the Medical sector's gain of 3.06% and the S&P 500's gain of 3.25%.The investment community will be paying close attention to the earnings performance of AbbVie in its upcoming ...

Company Overview - AbbVie announced positive topline results from the phase II PICCOLO study for Elahere, achieving an objective response rate (ORR) of 51.9% in patients with FRα-positive platinum-sensitive ovarian cancer [1] - The median duration of response (DOR) was reported at 8.25 months, but it was not confirmed if this met the study goal [1] - Elahere has received full FDA approval for treating FRα-positive, platinum-resistant ovarian cancer and is also approved in Europe [2] Drug Development and Pipeline - Elahere is being evaluated in multiple studies as both monotherapy and in combination with other drugs, aiming to expand its use in earlier lines of therapy [2] - AbbVie acquired ImmunoGen for $10.1 billion, adding Elahere and other promising antibody-drug conjugates (ADCs) to its oncology pipeline [2] - Other ADC candidates in AbbVie's pipeline include pivekimab sunirine and IMGN-151, which are in various stages of clinical trials [2] Industry Trends - The ADC market is gaining traction, with significant investments from major pharmaceutical companies like AstraZeneca, Merck, and Pfizer [3][6] - AstraZeneca's Enhertu has shown strong market uptake, generating approximately $339 million in alliance revenues in Q1 2024 [4] - Pfizer's acquisition of Seagen for $43 billion has added three ADCs to its portfolio, enhancing its presence in the ADC space [5] Market Performance - AbbVie's shares have increased by 8.8% over the year, compared to the industry's growth of 18.9% [2] - AbbVie currently holds a Zacks Rank 3 (Hold) [7]

Core Insights - Falling interest rates are leading money managers to shift towards income-oriented equities, particularly high-yield dividend stocks, as they offer yields above the S&P 500 [1] - The Federal Reserve may soon cut rates due to signs of a cooling labor market and core inflation, which is favorable for dividend stock investments [1] AbbVie (NYSE: ABBV) - AbbVie offers a dividend yield of 3.59% and has achieved a 10% annual dividend growth rate over the past five years, surpassing the 6% average among top dividend growers [2] - The stock trades at under 15 times forward earnings, making it attractively priced compared to the S&P 500's nearly 21 times forward earnings multiple [2] - Over the past five years, ABBV shares have appreciated by 117.71% [2] - AbbVie is managing the transition from the loss of market exclusivity for Humira, with strong sales from newer drugs like Skyrizi and Rinvoq, and Vraylar exceeding expectations [4][5] Pfizer (NYSE: PFE) - Pfizer has a dividend yield of 5.76% and is priced at less than 13 times future earnings, positioning it for potential outperformance over the next 10 to 20 years [6] - Despite trading below the S&P 500, Pfizer is a major player in the pharmaceutical industry with a promising pipeline [7] - PFE stock has declined by 29.17% over the past five years, primarily due to reduced revenue from COVID-19 product sales post-pandemic [8] - Pfizer's focus on oncology, which has strong pricing power, is often overlooked, but it remains a significant aspect of its long-term strategy [8] - Both AbbVie and Pfizer are suitable options for investors seeking high yields on long-term investments [8]

AbbVie (ABBV) dosed the first patient with ABBV-383, an investigational BCMA-CD3-targeted bispecific antibody, in the phase III CERVINO study to treat relapsed/refractory (r/r) multiple myeloma (MM).The CERVINO study will enroll nearly 380 patients with r/r MM who have received at least two lines of prior therapy. Patients will be randomized into two equal groups — either to receive a 60mg dose of intravenously-administered ABBV-383 once every four weeks or the investigator's choice of standard available th ...

Group 1 - AbbVie announced positive topline results from the Phase 2 PICCOLO trial for mirvetuximab soravtansine (ELAHERE®) in patients with platinum-sensitive ovarian cancer, achieving an objective response rate (ORR) of 51.9% [1] - The median duration of response (DOR) was reported at 8.25 months, indicating promising efficacy [1] - The safety profile of mirvetuximab soravtansine was consistent with previous studies, with no new safety concerns identified [1] Group 2 - The PICCOLO trial is a single-arm Phase 2 study focusing on patients with high folate receptor-alpha (FRα) positive platinum-sensitive ovarian cancer who have undergone at least two prior lines of platinum therapy [3] - The trial was designed to statistically rule out an ORR of 28% or lower, which is the response rate observed with non-platinum, single-agent chemotherapy in similar patient populations [3] - There is a significant unmet need for effective treatments in this patient group, as subsequent lines of therapy often show decreased efficacy and tolerability [2] Group 3 - Mirvetuximab soravtansine is also being evaluated in the Phase 3 GLORIOSA trial, which studies its combination with bevacizumab versus bevacizumab alone in maintenance therapy after second-line platinum-doublet therapy [4] - Ovarian cancer remains the leading cause of death from gynecological cancers in the U.S., with approximately 20,000 new diagnoses each year [5] - Patients who relapse after platinum-based chemotherapy are classified as either platinum-sensitive or platinum-resistant, impacting treatment options and outcomes [5][6] Group 4 - Mirvetuximab soravtansine is a first-in-class antibody-drug conjugate (ADC) designed to target and kill cancer cells expressing folate receptor alpha [7] - The drug has received regulatory approval in the U.S. for treating FRα positive, platinum-resistant ovarian cancer and is under review in Europe and other countries [8]

Core Points - Allergan Aesthetics is celebrating the 25th anniversary of SkinMedica® with a promotion for Allē Members, offering double points on purchases and a chance to win $5,000 [1][2] - SkinMedica® has established itself as a leader in the skincare industry since its founding in 1999, known for its science-backed formulations and innovative products [1][2] - The brand's co-founder, Dr. Kimberly Butterwick, emphasizes the importance of scientific innovation in skincare and expresses optimism for the future of SkinMedica® [2] Company Overview - Allergan Aesthetics, a subsidiary of AbbVie, develops and markets a range of aesthetic products, including injectables and skincare [4] - AbbVie focuses on delivering innovative medicines across various therapeutic areas, including aesthetics, and aims to address significant health challenges [5]

Core Points - AbbVie has launched the AbbVie Migraine Career Catalyst Award, a contest aimed at supporting the career aspirations of individuals living with migraine, with winners receiving up to $2,500 for career development [1][2][3] - The contest is a response to the significant impact of migraine on the workplace, with over 113 million workdays lost annually in the U.S. due to the condition [1][2] - Migraine is the second leading cause of disability globally, affecting nearly 40 million people in the U.S. alone, highlighting the need for support in both personal and professional realms [2][4] Company Initiatives - AbbVie is the only company offering three prescription treatments tailored to meet the diverse needs of migraine patients, demonstrating its commitment to addressing the challenges faced by this population [4] - The company aims to empower individuals living with migraine through education and partnerships, helping them navigate barriers to care and access effective treatments [4] - The contest encourages participants to share their experiences with migraine and career goals through essays, videos, or audio clips, fostering a supportive community [2][3] Contest Details - The submission period for the AbbVie Migraine Career Catalyst Award is open until September 3, 2024, with winners announced around November 15, 2024 [3] - The contest is open to legal residents of the U.S., D.C., and Puerto Rico, aged 18 or over, with no purchase necessary to enter [3] - Each prize has an approximate retail value of $2,500, aimed at assisting winners in their professional development [3]

Industry Overview - The biotech sector is rebounding after a challenging five years, with ongoing clinical trials and FDA approvals driving demand for life-changing drugs [1] - The industry is expected to maintain demand due to continuous product pipelines, approvals, and research [1] Company Summaries Novo Nordisk (NVO) - Novo Nordisk has seen a 35% increase in sales for its drug Wegovy, which reduces cardiovascular risks in obese individuals, with over 25,000 weekly users [2] - The company reported a 28% increase in net profit, reaching $25.4 billion in the first quarter, and raised its sales growth outlook to between 19% and 27% for the year [2] - NVO stock is up 37% year-to-date and has increased over 450% in the past five years, indicating strong momentum for future growth [3] Moderna (MRNA) - Moderna's stock is currently at $145, down from a high of $449 in 2021, but it has increased 45% year-to-date [4] - The company is testing a vaccine for avian flu and has 45 drugs in its pipeline, with many in final-stage trials, including a combination shot for flu and COVID-19 [4][5] - Revenue has declined to $167 million, with a projected full-year sales of $4 billion, but the company aims to return to sales growth next year and break even by 2026 [5] AbbVie (ABBV) - AbbVie stock is up 5% year-to-date and 18% over the past 12 months, currently trading at $162, and is considered undervalued [6] - The company has a diverse pipeline and recently partnered with Gilgamesh Pharmaceuticals to expand its psychiatric therapy offerings, capitalizing on the growing demand in this market [6] - AbbVie has over 90 compounds in its pipeline and has seen a 59% increase in sales for its drug Rinvoq, while maintaining a dividend yield of 3.82% [7]

Core Insights - High-yield dividend stocks are expected to benefit from potential interest rate cuts by the Federal Reserve due to signs of cooling in the U.S. labor market, economy, and core inflation [1] - AbbVie and Pfizer are highlighted as attractive high-yield dividend stocks with strong yields and favorable valuations [1] AbbVie - AbbVie offers a dividend yield of 3.87% and has increased its dividend by 10% annually over the past five years, outperforming the average 6% increase among top dividend growers [2] - The company's shares trade at under 15 times forward earnings, significantly lower than the S&P 500's nearly 21 times forward earnings [2] - AbbVie is managing the loss of market exclusivity for its key drug Humira effectively, with strong sales from newer immunology medications Skyrizi and Rinvoq, and positive performance from the neuroscience drug Vraylar [3] Pfizer - Pfizer has a dividend yield of 5.87% and is trading at less than 13 times future earnings, positioning it for long-term outperformance [4] - The company has faced revenue declines due to reduced sales of COVID-19 products and a lack of investor interest in its acquisitions [4] - Pfizer is shifting focus towards oncology, which is expected to provide strong pricing power and competitive advantages, making it a top pick for dividend investors [5]